Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

Clinical trial NCT01822509 · COMPLETED

Trial details

NCT number: NCT01822509
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Allogeneic Hematopoietic Stem Cell Transplant Recipient Myeloproliferative Neoplasm Recurrent Acute Lymphoblastic Leukemia Recurrent Acute Myeloid Leukemia Recurrent Chronic Lymphocytic Leukemia Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recurrent Hematologic Malignancy Recurrent Hodgkin Lymphoma Recurrent Myelodysplastic Syndrome Recurrent Non-Hodgkin Lymphoma Recurrent Plasma Cell Myeloma

Start date: 2013-05-16
Primary completion: 2018-12-31
Enrollment: 71

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.